ORGO Quote, Financials, Valuation and Earnings

BioXcel Therapeutics has a net margin of -21.74% compared to Organogenesis Holdings's net margin of -4317.86%. Organogenesis Holdings's return on equity of -5.05% beat BioXcel Therapeutics's return on equity of --.

Organogenesis Holdings has a consensus price target of $6.25, signalling upside risk potential of 110.44%. On the other hand BioXcel Therapeutics has an analysts' consensus of $48.00 which suggests that it could grow by 3353.24%. Given that BioXcel Therapeutics has higher upside potential than Organogenesis Holdings, analysts believe BioXcel Therapeutics is more attractive than Organogenesis Holdings.

Organogenesis Holdings has a beta of 1.848, which suggesting that the stock is 84.824% more volatile than S&P 500. In comparison BioXcel Therapeutics has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.161%.

Organogenesis Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioXcel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings pays -- of its earnings as a dividend. BioXcel Therapeutics pays out -- of its earnings as a dividend.

Organogenesis Holdings quarterly revenues are $86.7M, which are larger than BioXcel Therapeutics quarterly revenues of $168K. Organogenesis Holdings's net income of -$18.8M is lower than BioXcel Therapeutics's net income of -$7.3M. Notably, Organogenesis Holdings's price-to-earnings ratio is 70.39x while BioXcel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings is 0.85x versus 2.45x for BioXcel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of -21.74% compared to Organogenesis Holdings's net margin of -35.77%. Organogenesis Holdings's return on equity of -5.05% beat PROCEPT BioRobotics's return on equity of -29.12%.

Organogenesis Holdings has a consensus price target of $6.25, signalling upside risk potential of 110.44%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $76.88 which suggests that it could grow by 31.34%. Given that Organogenesis Holdings has higher upside potential than PROCEPT BioRobotics, analysts believe Organogenesis Holdings is more attractive than PROCEPT BioRobotics.

Organogenesis Holdings has a beta of 1.848, which suggesting that the stock is 84.824% more volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Organogenesis Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings pays -- of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend.

Organogenesis Holdings quarterly revenues are $86.7M, which are larger than PROCEPT BioRobotics quarterly revenues of $69.2M. Organogenesis Holdings's net income of -$18.8M is higher than PROCEPT BioRobotics's net income of -$24.7M. Notably, Organogenesis Holdings's price-to-earnings ratio is 70.39x while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings is 0.85x versus 12.48x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of -21.74% compared to Organogenesis Holdings's net margin of -21.61%. Organogenesis Holdings's return on equity of -5.05% beat RxSight's return on equity of -10.39%.

Organogenesis Holdings has a consensus price target of $6.25, signalling upside risk potential of 110.44%. On the other hand RxSight has an analysts' consensus of $21.18 which suggests that it could grow by 32.3%. Given that Organogenesis Holdings has higher upside potential than RxSight, analysts believe Organogenesis Holdings is more attractive than RxSight.

Organogenesis Holdings has a beta of 1.848, which suggesting that the stock is 84.824% more volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Organogenesis Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Organogenesis Holdings quarterly revenues are $86.7M, which are larger than RxSight quarterly revenues of $37.9M. Organogenesis Holdings's net income of -$18.8M is lower than RxSight's net income of -$8.2M. Notably, Organogenesis Holdings's price-to-earnings ratio is 70.39x while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings is 0.85x versus 4.29x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group has a net margin of -21.74% compared to Organogenesis Holdings's net margin of 17.89%. Organogenesis Holdings's return on equity of -5.05% beat TransMedics Group's return on equity of 23.22%.

Organogenesis Holdings has a consensus price target of $6.25, signalling upside risk potential of 110.44%. On the other hand TransMedics Group has an analysts' consensus of $126.71 which suggests that it could fall by -1.41%. Given that Organogenesis Holdings has higher upside potential than TransMedics Group, analysts believe Organogenesis Holdings is more attractive than TransMedics Group.

Organogenesis Holdings has a beta of 1.848, which suggesting that the stock is 84.824% more volatile than S&P 500. In comparison TransMedics Group has a beta of 1.906, suggesting its more volatile than the S&P 500 by 90.573%.

Organogenesis Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

Organogenesis Holdings quarterly revenues are $86.7M, which are smaller than TransMedics Group quarterly revenues of $143.5M. Organogenesis Holdings's net income of -$18.8M is lower than TransMedics Group's net income of $25.7M. Notably, Organogenesis Holdings's price-to-earnings ratio is 70.39x while TransMedics Group's PE ratio is 94.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings is 0.85x versus 9.62x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.